At a glance
ClinicalIndex Comparison RecordN/ACompleted· 189,426 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin
In Brief
An observational study for Diabetes Mellitus, Type 2. Completed, enrolled 189,426 participants across 1 site.
Detailed Summary
This protocol is for a series of comparative effectiveness and safety analyses within periodically updated cohorts of patients initiating linagliptin, other DPP-4 inhibitors, and other oral hypoglycemic medications, followed longitudinally for the occurrence of a variety of health outcomes. The primary analysis will be conducted among patients without prior within-class medication use.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartJul 2014
Primary CompletionFeb 2019
TodayJul 2026
First PostedJul 22, 2014
Enrollment StartJul 30, 2014
Primary CompletionFeb 26, 2019
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 11.9 years ago